ZASLOFF MICHAEL A 4

What Happened Michael A. Zasloff, a director of Amphastar Pharmaceuticals (AMPH), received equity awards on June 1, 2026: 8,143 shares represented by restricted stock units (RSUs) and a derivative award for 17,365 shares. Both awards were granted at a $0.00 purchase price (total reported value $0). These are grants (compensation), not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (timely filing).
• Grant details: 8,143 RSUs (reported as shares) + 17,365 derivative shares (reported as derivative award); combined total 25,508 shares.
• Price/Value: $0.00 per share; reported total consideration $0.
• Vesting: Footnote F1 — the RSUs vest on June 1, 2027. Footnote F2 — the derivative/option shares also vest on June 1, 2027.
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or late-filing indication noted in the report.

Context These awards are restricted/derivative grants that do not provide immediate tradable shares; they vest in one year (6/1/2027). Such grants are typical director compensation and should be read as compensation actions rather than direct signals of buying or selling intent. The derivative award will convert to shares only if and when vesting conditions are met.